TP53 AND KMT2D MUTATIONS PREDICT PFS IN MCL PATIENTS TREATED WITH HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: RESULTS FROM THE MCL0208 PHASE III TRIAL FROM FONDAZIONEITALIANA LINFOMI (FIL)

被引：0
|
作者：
Ferrero, S. [1 ]
Rossi, D. [2 ,3 ]
Bruscaggin, A. [2 ,3 ]
Ghione, P. [1 ]
Di Rocco, A. [4 ]
Spina, V. [2 ,3 ]
Stefoni, V. [5 ]
Ciccone, G. [6 ,7 ]
Barbero, D. [1 ]
Monitillo, L. [1 ]
Gomes da Silva, M. [8 ]
Santoro, A. [9 ]
Molinari, A. [10 ]
Ferreri, A. [11 ]
Piccin, A. [12 ]
Cortelazzo, S. [13 ]
Ladetto, M. [14 ]
Gaidano, G. [15 ]
机构：
[1] Univ Torino, Mol Biotechnol & Hlth Sci Hematol Div, Turin, Italy
[2] Oncol Inst Southern Switzerland, Hematol, Bellinzona, Switzerland
[3] Inst Oncol Res, Bellinzona, Switzerland
[4] Sapienza Univ Rome, Div Hematol, Rome, Italy
[5] Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, Inst Hematol & Med Oncol LA Seragnoli, Bologna, Italy
[6] Azienda Osped Univ Citta Salute & Sci Torino, Unity Clin Epidemiol, Turin, Italy
[7] CPO Piemonte, Turin, Italy
[8] Portuguese Inst Oncol, Lisbona, Portugal
[9] Humanitas Univ Canc Ctr, Milan, Italy
[10] Infermi Hosp, Rimini, Italy
[11] IRCCS San Raffaele Sci Inst, Unit Lymphoid Malignancies, Div Oncohematol Med, Dept Oncohematol, Milan, Italy
[12] San Maurizio Reg Hosp, Dept Haematol, Bolzano, Italy
[13] Clin Humanitas Gavazzeni, Unita Oncol, Bergamo, Italy
[14] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Div Hematol, Alessandria, Italy
[15] Univ Piemonte Orientale, Dept Translat Med, Hematol, Novara, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
C085
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 16 条
  • [1] TP53 AND KMT2D MUTATIONS PREDICT PFS IN MCL PATIENTS TREATED WITH HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: RESULTS FROM THE MCL0208 PHASE III TRIAL FROM FONDAZIONE ITALIANA LINFOMI (FIL)
    Ferrero, S.
    Rossi, D.
    Bruscaggin, A.
    Ghione, P.
    Di Rocco, A.
    Spina, V.
    Stefoni, V.
    Ciccone, G.
    Barbero, D.
    Monitillo, L.
    Gomes da Silva, M.
    Santoro, A.
    Molinari, A.
    Ferreri, A.
    Piccin, A.
    Cortelazzo, S.
    Ladetto, M.
    Gaidano, G.
    HAEMATOLOGICA, 2016, 101 : 272 - 272
  • [2] CLINICAL IMPACT OF TP53 AND KMT2D MUTATIONS IN MCL RECEIVING HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI MCL0208 PHASE III TRIAL
    Ferrero, S.
    Rossi, D.
    Bruscaggin, A.
    Evangelista, A.
    Di Rocco, A.
    Spina, V.
    Stefoni, V.
    Ghione, P.
    Barbero, D.
    Monitillo, L.
    da Silva, M. G.
    Santoro, A.
    Molinari, A.
    Ferreri, A.
    Piccin, A.
    Cortelazzo, S.
    Ladetto, M.
    Gaidano, G.
    HAEMATOLOGICA, 2017, 102 : 95 - 95
  • [3] CLINICAL IMPACT OF TP53 AND KMT2D MUTATIONS IN MCL RECEIVING HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI MCL0208 PHASE III TRIAL
    Ferrero, S.
    Rossi, D.
    Bruscaggin, A.
    Evangelista, A.
    Di Rocco, A.
    Spina, V.
    Stefoni, V.
    Ghione, P.
    Barbero, D.
    Monitillo, L.
    Gomes da Silva, M.
    Santoro, A.
    Molinari, A.
    Ferreri, A.
    Piccin, A.
    Cortelazzo, S.
    Ladetto, M.
    Gaidano, G.
    HAEMATOLOGICA, 2017, 102 : 2 - 3
  • [4] Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)
    Ladetto, Marco
    Ferrero, Simone
    Evangelista, Andrea
    Mian, Michael
    Di Rocco, Alice
    Coggi, Angela
    Rossi, Giuseppe
    Re, Alessandro
    Stefoni, Vittorio
    Cavallo, Federica
    Chiappella, Annalisa
    Santoro, Armando
    Rusconi, Chiara
    da Silva, Maria Gomes
    Gotti, Manuel
    Molinari, Anna Lia
    Ballerini, Filippo
    Ferreri, Andres J. M.
    Bosi, Alberto
    Narni, Franco
    Stelitano, Caterina
    Zamo, Alberto
    Ciccone, Gianni
    Vitolo, Umberto
    Martelli, Maurizio
    Cortelazzo, Sergio
    BLOOD, 2018, 132
  • [5] Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)
    Ferrero, Simone
    Grimaldi, Daniele
    Arrigoni, Elena
    Zaccaria, Gian Maria
    Alessandria, Beatrice
    Genuardi, Elisa
    De Luca, Gabriele
    Ghislieri, Marco
    Di Rocco, Alice
    Re, Alessandro
    Stefoni, Vittorio
    Cavallo, Federica
    Boccomini, Carola
    Balzarotti, Monica
    Zilioli, Vittorio Ruggero
    Maria, Gomes Da Silva
    Arcaini, Luca
    Molinari, Anna Lia
    Ballerini, Filippo
    Ferreri, Andres Jm
    Puccini, Benedetta
    Palumbo, Giuseppe A.
    Galimberti, Sara
    Cortelazzo, Sergio
    Di Paolo, Antonello
    Ladetto, Marco
    BLOOD, 2020, 136
  • [6] A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL)
    Rossi, Davide
    Ferrero, Simone
    Bruscaggin, Alessio
    Ghione, Paola
    Di Rocco, Alice
    Spina, Valeria
    Stefoni, Vittorio
    Ciccone, Giovannino
    Barbero, Daniela
    Monitillo, Luigia
    Da Silva, Maria Comes
    Santoro, Armando
    Molinari, Annalia
    Ferreri, Andres J. M.
    Cortelazzo, Sergio
    Ladetto, Marco
    Gaidano, Gianluca
    BLOOD, 2015, 126 (23)
  • [7] KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
    Ferrero, Simone
    Rossi, Davide
    Rinaldi, Andrea
    Bruscaggin, Alessio
    Spina, Valeria
    Eskelund, Christian W.
    Evangelista, Andrea
    Moia, Riccardo
    Kwee, Ivo
    Dahl, Christina
    Di Rocco, Alice
    Stefoni, Vittorio
    Diop, Fary
    Favini, Chiara
    Ghione, Paola
    Mahmoud, Abdurraouf Mokhtar
    Schipani, Mattia
    Kolstad, Arne
    Barbero, Daniela
    Novero, Domenico
    Paulli, Marco
    Zamo, Alberto
    Jerkeman, Mats
    da Silva, Maria Gomes
    Santoro, Armando
    Molinari, Annalia
    Ferreri, Andres
    Gronbaek, Kirsten
    Piccin, Andrea
    Cortelazzo, Sergio
    Bertoni, Francesco
    Ladetto, Marco
    Gaidano, Gianluca
    HAEMATOLOGICA, 2020, 105 (06) : 1604 - 1612
  • [8] KINETICS OF MINIMAL RESIDUAL DISEASE (MRD) DURING LENALIDOMIDE MAINTENANCE IN MANTLE CELL LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 MULTICENTER, PHASE III, RANDOMIZED TRIAL
    Grimaldi, D.
    Ferrero, S.
    Genuardi, E.
    Zaccaria, G. M.
    Alessandria, B.
    Ghislieri, M.
    Drandi, D.
    Evangelista, A.
    Ferrante, M.
    Mantoan, B.
    Stefani, P. M.
    Benedetti, F.
    Casaroli, I.
    Zanni, M.
    Castellino, C.
    Pavone, V.
    Petrini, M.
    Re, F.
    Hohaus, S.
    Musuraca, G.
    Cascavilla, N.
    Congiu, A. G.
    Liberati, A. M.
    Cortelazzo, S.
    Ladetto, M.
    HAEMATOLOGICA, 2020, 105 : S51 - S52
  • [9] Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL)
    Rinaldi, Andrea
    Ferrero, Simone
    Kwee, Ivo
    Rossi, Davide
    Bruscaggin, Alessio
    Spina, Valeria
    Diop, Fary
    Ballerini, Filippo
    Gherlinzoni, Filippo
    Benedetti, Fabio
    Mian, Michael
    Stelitano, Caterina
    Doni, Elisa
    Salvi, Alessandra Flavia
    Cortelazzo, Sergio
    Ladetto, Marco
    Gaidano, Gianluca
    Bertoni, Francesco
    BLOOD, 2016, 128 (22)
  • [10] Prognostic and Predictive Value of TP53 Mutations in Node-positive Breast Cancer Patients Treated with Anthracycline-or Anthracycline/taxane Based Adjuvant Therapy - Results From the BIG 02-98 Phase III Trial
    Olivier, M.
    Fernandez-Cuesta, L.
    Oakman, C.
    Quinaux, E.
    Dolci, M. S.
    Francis, P. A.
    Piccart-Gebhart, M.
    Viale, G.
    Di Leo, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S180 - S181
12